<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eight patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; RA = 1, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> = 2, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t = 4, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> = 1) received three cycles of recombinant gamma-IFN administered in 2-week intervals, each consisting of a 14-day period of subcutaneous injections at a daily dose of 0.1 mg/m2 </plain></SENT>
<SENT sid="1" pm="."><plain>Neither a complete nor a partial remission could be obtained </plain></SENT>
<SENT sid="2" pm="."><plain>There was only one definite improvement consisting in a rise of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level from 7 to more than 12 g/dl </plain></SENT>
<SENT sid="3" pm="."><plain>Two minor improvements were due to a slight rise of platelet counts </plain></SENT>
<SENT sid="4" pm="."><plain>Three patients developed <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> under treatment with gamma-IFN </plain></SENT>
<SENT sid="5" pm="."><plain>Our data suggest that gamma-IFN administered according to the treatment schedule as used in our trial has only a minimal beneficial effect in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>